Testosteronsubstitutionsbehandling af hypogonadisme hos mænd med prostatacancer

Christian F S Jensen, Mikkel Fode, Peter Østergren, Jens Sønksen

Abstract

Hypogonadism and prostate cancer (PCa) often coincide with increasing age. Recent reviews have found no evidence to suggest an increased risk of developing PCa with testosterone replacement therapy (TRT). The same lack of PCa risk is found in studies looking at men receiving TRT after radical prostatectomy for PCa. Reports on TRT in men on active surveillance are very few. In summary, current evidence does not support an association between TRT and an increased risk of PCa. Nevertheless, sufficiently powered trials with longer follow-up are warranted before making final conclusions.

Bidragets oversatte titelTestosterone replacement therapy for hypogonadism in men with prostate cancer
OriginalsprogDansk
ArtikelnummerV10160711
TidsskriftUgeskrift for Laeger
Vol/bind179
Udgave nummer9
Antal sider5
ISSN0041-5782
StatusUdgivet - 2017

Fingeraftryk

Dyk ned i forskningsemnerne om 'Testosteronsubstitutionsbehandling af hypogonadisme hos mænd med prostatacancer'. Sammen danner de et unikt fingeraftryk.

Citationsformater